Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful
consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently
present in patients with epilepsy, they are more common in those patients with pharmacoresistant
epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant
seizure control are not available for all patients and/or present disadvantages. Moreover, the
conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this
field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological
conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic
strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of
pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional